ARNI在常见心血管及相关疾病中应用的研究进展

Research progress on ARNI in treatment of cardiovascular and related diseases

心力衰竭是各种心血管疾病的严重和终末阶段,具有很高的发病率和病死率。沙库巴曲缬沙坦钠是第1种血管紧张素受体脑啡肽酶抑制剂(ARNI),在治疗慢性心力衰竭方面比血管紧张素转换酶抑制剂(ACEI)及血管紧张素受体拮抗剂(ARB)有更大优势。目前多项心力衰竭诊疗指南已将ARNI作为治疗心力衰竭的一线用药。近些年多项实验室及临床研究表明ARNI在高血压、心律失常、心肌梗死、糖尿病和糖尿病肾病等其他疾病治疗中具有巨大潜力。本文就ARNI在心血管及相关疾病治疗中的有效性及安全性的研究进展进行综述。

Heart failure is a serious and terminal stage of various cardiovascular diseases,with high morbidity and mortality.Sacubitril/valsartan is the first angiotensin receptor neprilysin inhibitor(ARNI).The efficacy and safety of ARNI in treating chronic heart failure are significantly better than angiotensin-converting enzyme inhibitors(ACEI)and angiotensin receptor blockers(ARB).At present,ARNI has been used as a first-line drug in the treatment of heart failure in several guidelines for the diagnosis and treatment of heart failure.Several laboratory and clinical studies revealed the great potential of ARNI in treating hypertension,arrhythmia,myocardial infarction,diabetes,diabetic nephropathy,and other cardiovascular diseases.In this paper,we review the latest research progress of the efficacy and safety of ARNI in cardiovascular and other related diseases.